Trial results

Albiglutide Versus Placebo Added-on to Basal-Bolus Insulin Therapy in Subjects With Type 2 Diabetes Mellitus

NCT02229240 on ClinicalTrials.gov · last registry update 2016-01-11

Withdrawn before anyone was enrolled. The sponsor logged completion for December 2015. Primary outcome, as filed: Percentage of subjects with severe or documented symptomatic hypoglycemia through Week 26. albiglutide is not approved in the US for anything yet, so this is a drug in development rather than an established treatment being extended. The registry entry has been edited 1 time since then.

Status

WITHDRAWN

Phase

P3

Drug

albiglutide

Tanzeum

Sponsor

GlaxoSmithKline

Sponsor type

Industry

Enrollment

0

Started

2015-08

Primary completion

2015-12 estimated

Observed history

Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.

Primary outcome

Percentage of subjects with severe or documented symptomatic hypoglycemia through Week 26

Conditions studied

Diabetes Mellitus, Type 2

Every field above is taken directly from the registry record. See all detected changes across the class, or the albiglutide page for this molecule’s full trial and approval history.